176 related articles for article (PubMed ID: 34549913)
1. An Overview of Organoid and 3-Dimensional Models in Multiple Myeloma.
Rodriguez C
Cancer J; 2021 May-Jun 01; 27(3):239-246. PubMed ID: 34549913
[TBL] [Abstract][Full Text] [Related]
2. 3D tissue-engineered bone marrow as a novel model to study pathophysiology and drug resistance in multiple myeloma.
de la Puente P; Muz B; Gilson RC; Azab F; Luderer M; King J; Achilefu S; Vij R; Azab AK
Biomaterials; 2015 Dec; 73():70-84. PubMed ID: 26402156
[TBL] [Abstract][Full Text] [Related]
3. Noncoding RNAs in the crosstalk between multiple myeloma cells and bone marrow microenvironment.
Tang W; Xu J; Xu C
Cancer Lett; 2023 Mar; 556():216081. PubMed ID: 36739065
[TBL] [Abstract][Full Text] [Related]
4. The Role of Marrow Microenvironment in the Growth and Development of Malignant Plasma Cells in Multiple Myeloma.
Giannakoulas N; Ntanasis-Stathopoulos I; Terpos E
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33923357
[TBL] [Abstract][Full Text] [Related]
5. Modeling multiple myeloma-bone marrow interactions and response to drugs in a 3D surrogate microenvironment.
Belloni D; Heltai S; Ponzoni M; Villa A; Vergani B; Pecciarini L; Marcatti M; Girlanda S; Tonon G; Ciceri F; Caligaris-Cappio F; Ferrarini M; Ferrero E
Haematologica; 2018 Apr; 103(4):707-716. PubMed ID: 29326121
[TBL] [Abstract][Full Text] [Related]
6. A preclinical assay for chemosensitivity in multiple myeloma.
Khin ZP; Ribeiro ML; Jacobson T; Hazlehurst L; Perez L; Baz R; Shain K; Silva AS
Cancer Res; 2014 Jan; 74(1):56-67. PubMed ID: 24310398
[TBL] [Abstract][Full Text] [Related]
7. Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities.
Shay G; Hazlehurst L; Lynch CC
J Mol Med (Berl); 2016 Jan; 94(1):21-35. PubMed ID: 26423531
[TBL] [Abstract][Full Text] [Related]
8. Drug resistance in multiple myeloma: novel therapeutic targets within the malignant clone.
Pilarski LM; Mant MJ; Belch AR
Leuk Lymphoma; 1999 Jan; 32(3-4):199-210. PubMed ID: 10037018
[TBL] [Abstract][Full Text] [Related]
9. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Chung C
Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
[TBL] [Abstract][Full Text] [Related]
10. Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment.
Lam C; Ferguson ID; Mariano MC; Lin YT; Murnane M; Liu H; Smith GA; Wong SW; Taunton J; Liu JO; Mitsiades CS; Hann BC; Aftab BT; Wiita AP
Haematologica; 2018 Jul; 103(7):1218-1228. PubMed ID: 29622655
[TBL] [Abstract][Full Text] [Related]
11. Novel therapeutic strategies for multiple myeloma.
Mimura N; Hideshima T; Anderson KC
Exp Hematol; 2015 Aug; 43(8):732-41. PubMed ID: 26118499
[TBL] [Abstract][Full Text] [Related]
12. Susceptibility of multiple myeloma to B-cell lymphoma 2 family inhibitors.
Lernoux M; Schnekenburger M; Dicato M; Diederich M
Biochem Pharmacol; 2021 Jun; 188():114526. PubMed ID: 33741332
[TBL] [Abstract][Full Text] [Related]
13. Old and Young Actors Playing Novel Roles in the Drama of Multiple Myeloma Bone Marrow Microenvironment Dependent Drug Resistance.
Manni S; Carrino M; Semenzato G; Piazza F
Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29783691
[TBL] [Abstract][Full Text] [Related]
14. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets.
Hideshima T; Mitsiades C; Tonon G; Richardson PG; Anderson KC
Nat Rev Cancer; 2007 Aug; 7(8):585-98. PubMed ID: 17646864
[TBL] [Abstract][Full Text] [Related]
15. Multiple myeloma: the bone marrow microenvironment and its relation to treatment.
Andrews SW; Kabrah S; May JE; Donaldson C; Morse HR
Br J Biomed Sci; 2013; 70(3):110-20. PubMed ID: 24273897
[TBL] [Abstract][Full Text] [Related]
16. Molecular Crosstalk between Chromatin Remodeling and Tumor Microenvironment in Multiple Myeloma.
Chakraborty C; Mukherjee S
Curr Oncol; 2022 Dec; 29(12):9535-9549. PubMed ID: 36547163
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma.
Yang WC; Lin SF
Biomed Res Int; 2015; 2015():341430. PubMed ID: 26649299
[TBL] [Abstract][Full Text] [Related]
18. Patient-Derived Multiple Myeloma 3D Models for Personalized Medicine-Are We There Yet?
Lourenço D; Lopes R; Pestana C; Queirós AC; João C; Carneiro EA
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361677
[TBL] [Abstract][Full Text] [Related]
19. Exosomal miRNAs in the Tumor Microenvironment of Multiple Myeloma.
Alipoor SD; Chang H
Cells; 2023 Mar; 12(7):. PubMed ID: 37048103
[TBL] [Abstract][Full Text] [Related]
20. N-cadherin-mediated interaction with multiple myeloma cells inhibits osteoblast differentiation.
Groen RW; de Rooij MF; Kocemba KA; Reijmers RM; de Haan-Kramer A; Overdijk MB; Aalders L; Rozemuller H; Martens AC; Bergsagel PL; Kersten MJ; Pals ST; Spaargaren M
Haematologica; 2011 Nov; 96(11):1653-61. PubMed ID: 21828122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
